Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

Merck & Co., Inc. Acquisition Discussions - Merck & Co., Inc. has ended discussions to acquire Revolution Medicines due to disagreements on valuation, with the potential deal previously valued between $28 billion and $32 billion [1][2] - The talks had valued Revolution Medicines at approximately $30 billion, indicating Merck's disciplined approach to deal size despite interest in high-growth oncology assets [2] Merck's Acquisition Strategy - Merck's CEO Robert Davis stated that the company is primarily targeting acquisitions valued at $15 billion or less, while remaining open to larger transactions under favorable conditions [3] - AbbVie Inc. was also reportedly in advanced talks to acquire Revolution Medicines, although further details were not disclosed [3] Market Reaction and Valuation Shift - Prior to acquisition speculation, Revolution Medicines had a market value of about $16 billion, which surged to over $22 billion following the news [4] - Following the end of discussions, Revolution Medicines shares fell by 22.74% to $90.88 during premarket trading, while Merck shares increased by 0.15% to $108.34 [8] Future Deal Prospects - Despite the current setback, there is potential for talks to restart or for another bidder to emerge, as investor attention builds ahead of upcoming clinical updates [6] - Revolution Medicines is expected to release important trial data for its pancreatic and colorectal cancer drug candidates in the first half of the year [6] Revolution Medicines' Product Pipeline - Revolution Medicines is focused on developing targeted cancer therapies, particularly for the RAS molecular driver, which has been challenging to target [5] - The company's experimental pancreatic cancer treatment could potentially generate up to $10 billion in annual sales by 2035, highlighting its attractiveness for acquisition [5] Clinical Trials - Revolution Medicines' daraxonrasib (RMC-6236) for pancreatic cancer is included in the FDA's National Priority Voucher program and is being studied in two global Phase 3 clinical trials [7]